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L iquid chromatography–mass spectrometry method for the analysis
of the anti-cancer agent capecitabine and its nucleoside metabolites
in human plasma
Yan Xu , Jean L. Grem
Abstract
A reversed-phase high-performance liquid chromatography method with electrospray ionization and mass spectral
detection is described for the determination of capecitabine, 59-deoxy-5-fluorocytidine and 59-deoxy-5-fluorouridine in
human plasma with 5-chloro-29-deoxyuridine as the internal standard. An on-line sample clean-up procedure allows dilution
of the plasma sample with the initial mobile phase. The linear dynamic range is 0.0500–10.0 mg/ml for capecitabine, and
0.0500–25.0 mg/ml for the metabolites, 59-deoxy-5-fluorocytidine and 59-deoxy-5-fluorouridine, respectively. This method
has been used to analyze plasma samples from patients receiving capecitabine in combination with oxaliplatin.
Published by Elsevier Science B.V.
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Introduction drug has also been approved for treatment of patients
with metastatic colorectal cancer [3,4]. This agent is
4Capecitabine (N -pentoxycarbonyl-59-deoxy-5- absorbed intact as the parent drug through the
fluorocytidine, Xeloda) is the first oral prodrug of gastrointestinal mucosa, and then undergoes a three-
5-fluorouracil (5-FU) to be approved in the United step enzymatic conversion that results in the release
States, based on its activity in patients with meta- of 5-FU [5]. Hepatic carboxylesterase yields 59-
static breast cancer whose disease has progressed deoxy-5-fluorocytidine (59-DFCR), which is then
after two prior chemotherapy regimens [1,2]. The converted by cytidine deaminase, a widely distribut-
ed enzyme in plasma and tissues, to 59-deoxy-5-
fluorouridine (59-DFUR); finally, thymidine phos-
phorylase generates 5-FU (Fig. 1). 5-FU is enzymati-
cally cleared from plasma, and the initial, rate-limit-
ing step is catalyzed by dihydropyrimidine dehydro-
genase to produce dihydro-5-fluorouracil; two sub-
sequent steps result in the formation of fluoro-
ureidopropionic acid and a-fluoro-b-alanine (FBAL),
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Fig. 1. Metabolism of capecitabine. The enzymes are as follows: 1, carboxylesterase; 2, cytidine deaminase; 3, thymidine phosphorylase; 4,
dihydropyrimidine dehydrogenase; 5, dihydropyrimidinase; 6, b-alanine synthase.
respectively, with release of CO and NH [6]. of a cytidine deaminase inhibitor. Over the dose2 3
Although FBAL does not have anti-cancer activity, it range used clinically, there is no evidence of dose-
is thought to contribute to some host toxicities. dependency in the pharmacokinetic parameters.
Clinical studies have documented rapid gastrointesti- In conjunction with an ongoing phase I clinical
nal absorption of the parent drug with efficient trial that employs escalating doses of capecitabine in
conversion to 59-DFUR [7,8]. Systemic levels of combination with oxaliplatin, we plan to measure the
5-FU have generally been about fivefold lower on a pharmacokinetics of capecitabine given alone and
molar basis than the plasma levels of the parent with oxaliplatin. The methods initially developed by
compound, providing evidence of intracellular for- Roche Laboratories used two different liquid chro-
mation of 5-FU. matography columns and separation conditions for
The most commonly used clinical schedule in- the analysis of capecitabine and 59-DFCR/59-DFUR,
volves administration of capecitabine daily for 14 respectively [9]. A proprietary liquid chromatog-
days every 3 weeks, and the recommended single raphy tandem mass spectrometry (LC–MS–MS)
2
agent dose is 2500 mg/m p.o. daily given as two method was subsequently developed by Roche Lab-
equal doses about 12 h apart, taken within 30 min oratories; sufficient details have not been provided to
after a meal. Dose-limiting toxicities include diar- permit exact replication of the method [10]. Further,
rhea, nausea, vomiting, and palmar-plantar erythro- MS–MS is a relatively expensive technology, while
dysesthesia, while myelosuppression is uncommon mass spectral detection with a single quadrupole is
[1–4]. more often available in a research laboratory setting.
The pharmacokinetics of capecitabine, 59-DFCR, We describe herein a combined analytical method
and 59-DFUR were initially measured by a liquid that permits the simultaneous measurement of plas-
chromatography method with ultraviolet detection ma capecitabine, 59-DFCR, and 59-DFUR with direct
developed by the pharmaceutical sponsor, while the sample injection. This method involves on-line plas-
the pharmacokinetics of 5-FU and its catabolites ma sample extraction, reversed-phase liquid chro-
were measured by gas chromatography with mass matographic separation, and electrospray-ionization
spectral detection (GC–MS) [9]. The time at which mass spectrometric detection that is suitable for
the maximum plasma concentrations (C ) for analysis of plasma samples from patients receivingmax
capecitabine, the nucleoside metabolites and 5-FU capecitabine therapy.
are reached has varied among patients, ranging from
0.5 to 3 h after oral dosing. The apparent elimination
half-lives (t ) are |1 h for all metabolites except Experimental1 / 2
for FBAL, which has an initial half-life of about 2.6
h. The area under the plasma concentration–time Chemicals and solutions
curve (AUC) of 59-DFUR is reported to be about
threefold higher than that of 59-DFCR when the Ammonium acetate (99.999%) was from Aldrich
peripheral blood samples are collected in the absence (Milwaukee, WI, USA). HPLC grade water was from
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Table 1Fisher (Fair Lawn, NJ, USA). High purity acetoni-
Gradient elution methodtrile (Cat. no. 015-4) and methanol (Cat. no. 230-4)
Time (min) % A % B Flow (ml /min) Curvewere from Burdick & Jackson (Muskegon, MI,
USA). 59-DFUR (C H FN O , M 246.2, CAS 0.0 100 0 3.0 19 11 2 4 w
registry 3094-09-5), 5-chloro-29-deoxyuridine (5- 0.8 100 0 3.0 1
1.0 100 0 0.2 1CUDR), 5-fluorouridine (FUR), and 5-fluoro-29-de-
2.0 100 0 0.2 1oxyuridine (5-FUDR) were from Sigma (St. Louis,
2.2 90 10 0.2 6MO, USA). Capecitabine (C H FN O , M 359.4,15 22 3 6 w 10.0 70 30 0.2 6
CAS registry 154361-50-9; lot no. 26954-190A- 12.0 30 70 0.2 6
MIL) and 59-DFCR (C H FN O , M 245.2, Ro 15.0 30 70 0.2 19 12 3 3 w
15.2 100 0 0.2 621-8782, lot no. 5206-262) were generously pro-
20.0 100 0 0.2 1vided by Hoffmann-La Roche (Nutley, NJ, USA).
20.2 5 95 3.0 6Tetrahydrouridine (lot no. 112907-J /22) was pro- 21.2 5 95 3.0 1
vided by the Drug Synthesis and Chemistry Branch, 21.4 100 0 3.0 6
Division of Cancer Treatment and Diagnosis, Na- 24.0 100 0 3.0 11
tional Cancer Institute (Bethesda, MD, USA). Pooled Solvent A, 5 mM ammonium acetate at pH 6.8; solvent B,
donor human plasma was obtained from the Depart- acetonitrile. See Waters 2690 Separations Module Operator’s
Guide, Table 6.4. The specified curve number sets the rate atment of Transfusion Medicine in the Clinical Center,
which the solvent is to change to the new proportions and/orNational Institutes of Health (Bethesda, MD, USA).
flow-rate: curve number 6 is a linear gradient; curves 1 and 11 areA stock solution of ammonium acetate (100 mM,
step gradients that proceed instantaneously from initial to final
pH 6.8) was prepared by dissolving appropriate conditions either at the start or end of the time interval.
amounts of ammonium acetate in a known volume of
HPLC grade water, and 5 mM ammonium acetate at
pH 6.8 was prepared by 1:20 dilution of the stock gave written, informed consent. For the phar-
solution with HPLC grade water and used as the macokinetic studies, blood samples were obtained
solvent A in the gradient elution. Acetonitrile was from an indwelling intravenous cannula (heparin
used as the solvent B (Table 1). lock) prior to dosing, and then 0.5, 1, 2, 3, 4, 6 and 8
Standard stock solutions of capecitabine, 59-DFCR h after the initial dose of capecitabine given alone,
and 59-DFUR at the concentration of 10.0 mg/ml, and again on the first day of the second cycle in
and internal standard stock solution of 5-CUDR at which oxaliplatin was given as a 2-h infusion by vein
the concentration of 500 mg/ml were prepared by prior to the oral dose of capecitabine. The blood
dissolving appropriate amounts of compounds in a samples were collected in 10-ml green-top
known volume of methanol. Standard mixture work- Vacutainer tubes (Becton Dickinson, Franklin
ing solutions of capecitabine, 59-DFCR and 59- Lakes, NJ, USA) containing sodium heparin and 10
DFUR at the concentrations of 0.50, 1.00, 5.00, 10.0, nmol tetrahydrouridine, an inhibitor of cytidine
2750.0, 100, 200 and 500 mg/ml were prepared by deaminase (K 10 M). The samples were immedi-i
mixing and serial dilutions of the stock solutions ately placed on ice and transported to the laboratory,
with methanol. An internal standard working solu- where they were centrifuged for 10 min at 800 g
tion at the concentration of 50.0 mg/ml was prepared (4 8C). The plasma was transferred into three labeled
by a 10-fold dilution of the stock solution with 2.0-ml cryogenic vials (Nalge Nunc, Rochester, NY,
methanol. USA) and stored at 270 8C until analysis.
Blood sampling Preparation of blank plasma, calibrators and
patient samples
The blood samples were collected from colorectal
cancer patients participating in an Institutional Re- Pooled human plasma from voluntary blood
view Board-approved phase I clinical study of oral donors containing 1 mM tetrahydrouridine was used
capecitabine alone and with oxaliplatin. All patients as the blank plasma in this study. Fifty ml of a
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standard mixture solution of capecitabine, 59-DFCR Deerfield, IL, part no. 85526), and a PC station with
and 59-DFUR at each concentration level and 50 ml MassLynx NT (Version 3.4) software (Micromass,
of the internal standard solution (5-CUDR, 50.0 Manchester, UK) for data acquisition. The fluid
mg/ml) were added to 1.5-ml centrifuge tubes processor was electrically connected to switch 4 of
(Marsh Bio Products, Rochester, NY, USA). The the I /O signal connector A in the rear panel of the
solutions were dried in an Eppendorf Vacufuge Waters 2690 separations module. The fluidic con-
concentrator (Brinkmann Instruments, Westbury, NY, nection of the system is shown in Fig. 2. At position
USA) at 30 8C for 20 min. Then, aliquots of blank A, the eluent from the pump carried the sample from
plasma (500 ml each) were added. For the patient the autosampler to the extraction column (Waters
samples, 50 ml internal standard solution (5-CUDR, Oasis HLB cartridge column, 2.1 mm320 mm,
50.0 mg/ml) alone were added to 1.5-ml centrifuge part no. 186000706) and the sample matrix was
tubes, and the solution was dried in an Eppendorf excluded to the waste. At position B, the gradient
Vacufuge at 30 8C for 20 min. Aliquots of patient eluent from the pump eluted the analytes and the
plasma (500 ml each) were then added. internal standard from the extraction column and
The above blank plasma, calibrators, and patient carried them through the C guard column18
samples were diluted with equal volumes of 5 mM (SecurityGuard, part no. KJO-4282, Phenomenex,
ammonium acetate (pH 6.8). After vortex mixing, Torrance, CA, USA) to the analytical column (Wa-
˚these samples were put on ice for 15 min before ters YMC ODS-AQ 5 mm, 120 A, 2.0 mm3150 mm,
centrifugation at 3000 g at 41 8C for 10 min. The part no. AQ12S051502WT). The eluate of the ana-
sample solutions were transferred to autosampler lytical column was diverted to the mass spectrometer
vials (Waters, part no. 186000326), taking care to (ESI-MS detector) and the spectrophotometer (PDA
avoid any fat floating on the top and the precipitate, detector) via a PEEK microvolume connector (Cat.
followed by instrument analysis. no. MT1XCPK, Valco Instruments, Houston, TX)
with a post-column split ratio of 1:2. The smaller
Recovery studies flow went to the ESI-MS detector and the larger one
to the PDA detector. High pressure PEEK tubing was
The recoveries of capecitabine, 59-DFCR, 59- used for all connections. The tubing prior to the inlet
DFUR and 5-CUDR were determined by comparing of the analytical column was 1/16 inch O.D. and
the mean of peak areas of the plasma samples 0.01 inch I.D., and the one after the analytical
prepared from blank plasma spiked with the com- column was 1/16 inch O.D. and 0.005 inch I.D.
pounds at three concentration levels (0.250, 2.50 and
25.0 mg/ml) to the mean of the peak areas of the
control samples prepared from 5 mM ammonium
acetate (pH 6.8) spiked with analytes and internal
standard at the same levels. The sample preparation
procedure was the same as those described for the
calibrators (see Section 2.3).
Instrumentation
The system used for this work could perform the
following tasks: (a) on-line sample extraction, (b) LC
separation, and (c) ESI-MS and UV detection. The
system included a Waters 2690 separations module, a
Waters 996 photodiode array (PDA) detector, a
Micromass Platform LC mass spectral detector (Wa- Fig. 2. Block diagram of the instrument system. Position A
ters, Milford, MA, USA), a Rheodyne LabPRO two- (dashed line), for the on-line sample extraction; position B (solid
position (6-Port, PEEK) fluid processor (Alltech, line), for the LC–ESI-MS detection.
276
Chromatographic conditions mode over the mass range of 200–400 amu at the
scan rate of 200 amu/s. Single-ion-monitoring (SIM)
The operation conditions of Waters 2960 sepa- mode was used for sample quantitation by sequen-
rations module were set as follows: sample tempera- tially monitoring quasi-molecular ions of each ana-
2ture, 41 8C; analytical column temperature, 30 8C; lyte: m /z 245, [59-DFUR2H] ; m /z 246, [59-
1 2
extraction column temperature, ambient; sample DFCR1H] ; m /z 261, [5-CUDR2H] ; and m /z
1injection volume, 20 ml. The method used gradient 360, [capecitabine1H] . Data acquisition was car-
elution for on-line sample extraction and LC–MS ried out with a dwell time of 0.50 s, a span of 0.00
analysis with a total run time of 24 min (Table 1). Da, repeats of 1, and inter-channel delay of 0.05 s.
The switching valve of the fluid processor diverted The cone voltages were 35, 15, 35 and 20 V for ion
the effluent of the extraction column to the waste for masses 245, 246, 261 and 360, respectively.
the first eight-tenths of a minute to prevent plasma
proteins and other polar matrix interferences from Data analysis
entering the analytical column (position A, Fig. 2).
The valve was switched to the position B at the The plasma concentrations were determined by
eight-tenth min to redirect the flow to the analytical
comparing the peak area ratios for each analyte of
column. The valve was switched back to the initial interest to the internal standard in the patient samplesposition (position A) at 19.90 min for re-condition-
to the ratios generated from the calibration curve.ing the extraction column. Non-compartmental methods were used to analyze
the clinical sample data using WinNonLin ProESI-MS detection
version 3.2 (Pharsight Corp., Mountain View, CA,
USA). The AUC was determined by the linearThe mass spectrometer was operated in both the
trapezoidal rule, and the half-life was estimated frompositive and the negative modes of electrospray
the terminal portion of the curve.ionization (ESI1 and ESI2). It was tuned by the
infusion of an analyte mixture (50.0 mg/ml each in 5
mM ammonium acetate, pH 6.8) with a Harvard
syringe pump (Harvard Apparatus, South Natick, Results and discussion
MA, USA, Cat. no. 55-1111) at a flow-rate of 10
ml /min via 0.005 inch I.D. PEEK tubing. The Sample preparation
sample was converged with the incoming LC mobile
phase (5 mM ammonium acetate, pH 6.8 at flow-rate In this work, the blank plasma, calibrators, and
of 0.2 ml /min) in a sample tee prior to delivery into patient samples were first diluted with equal volumes
the MS detector. The optimized ionization conditions of 5 mM ammonium acetate, pH 6.8. Then, the
are summarized in Table 2. sample solutions were mixed, iced, and centrifuged
Full scan spectra were acquired in the centroid before transferring to autosampler vials for the LC–
ESI-MS analysis.
After these steps, some of the patient plasmaTable 2
samples had a whitish floating layer (probably fat)Electrospray ionization conditions
and a precipitate (probably fibrin). These phenomena
Parameters ESI1 ESI2
were not observed with the blank plasma samples; a
24 24Analytical vacuum ,1.0310 mBar ,1.0310 mBar reasonable explanation may be that the blank plasma
Nitrogen gas 400 l /h 400 l /h
was, in general, from young healthy donors, whileCapillary 3.50 kV 2.70 kV
the blood samples were from older cancer patientsCone 220 kV 35 V
who had taken capecitabine within 30 min after aSource heater 140 8C 140 8C
LM resolution 14.5 15.0 meal. Care was taken during the transfer of the
HM resolution 14.5 15.5 diluted supernatant to the autosampler vial to avoid
Ion energy 0.3 V 0.8 V the precipitate and the globular material on the
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surface. To prevent experimental errors, the same acronym for hydrophilic lipophilic balance that
procedures were used in the preparation of blank describes the dual retention capability of the sorbent
plasma, calibrators, and patient plasma samples. to retain polar and non-polar compounds. The water-
wettable macroporous sorbent of Oasis HLB can
On-line sample extraction exclude plasma proteins and other matrix con-
stituents, while retaining the analytes of interest
An on-line sample extraction is an in situ solid- under the optimized conditions with high and re-
phase extraction, which includes loading of the producible recoveries.
sample, exclusion of macromolecules while retaining Fig. 3 shows the gradient elution profiles of the
the analytes, followed by elution of the analytes. A extraction cartridge with the eluent directed to the
major advantage of on-line sample extraction over photodiode array detector. These profiles indicate
off-line solid-phase extraction (SPE) or liquid–liquid that plasma proteins and other macromolecules could
extraction in plasma sample preparation is that direct be excluded from the column within 48 s after the
sample injection requires minimum sample handling, sample injection, whereas capecitabine, 59-DFCR,
improves sample throughput and reproducibility, and 59-DFUR, 5-CUDR (I.S.) and other endogenous
is ready for automation. compounds did not elute before 7 min. For the first
Because of the hydrophilic and lipophilic nature of 0.8 min after the sample injection, the column
the nucleosides, an Oasis HLB cartridge column was effluent was diverted to the waste; thereafter, the
used as the extraction column for the on-line sample switching valve controlled by the MassLynx NT
preparation. Based on the product information, software was turned to position B, which was in-line
Oasis HLB sorbent is a copolymer of [poly(di- with the guard column, the analytical column, and
vinylbenzene-co-N-vinylpyrrolidone)]. HLB is an the ESI-MS detector. The analytes of interest to-
Fig. 3. Elution profiles of analytes in 5 mM ammonium acetate, pH 6.8 (bottom trace), blank plasma (middle trace), and analytes in blank
plasma (top trace) from Oasis HLB cartridge column. The instrument system was in position B, except the guard and analytical columns
were removed; PDA detection was set over the range of 200–400 nm, the analytes were at 25.0 mg/ml each and the gradient elution method
outlined in Table 1 was employed.
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gether with other endogenous compounds were work, since 5-DFCR shares the same mass-to-charge
eluted from the extraction column by the gradient of (m /z) ratio with an unknown, 5-DFUR shares the
5 mM ammonium acetate (pH 6.8) and acetonitrile same m /z ratio with 5-FUDR, and 5-CUDR shares
(Table 1), separated on the analytical column, and the same m /z ratio with 5-FUR and an unknown
detected by the ESI-MS detector. (Fig. 5), the separation of these compounds directly
In the method developed, at 19.90 min after the affected the selectivity and specificity of the ana-
sample injection, the switching valve was changed to lytical method. Among the analytes of interest,
divert the eluate to the waste, and the extraction except for capecitabine, the other compounds are
column was then flushed with 95% acetronitrile–5% quite hydrophilic in nature. Since these compounds
5 mM ammonium acetate and equilibrated with 5 elute rapidly from reversed-phase columns with
mM ammonium acetate (the extraction buffer). Due mobile phases containing a low percentage of or-
to the sufficient washing prior to the next sample ganic content, they presented a challenge to the
injection, no analyte carryover was observed in this chromatographic method development.
method. For this work, we had tested several reversed-
phase columns for the separation of the analytes
from the interfering compounds, which include Sym-
metry C , YMC Basic, XTerra C , Nova-Pak C ,18 18 18ESI-MS detection
and YMC ODS-AQ columns (Waters Corporation).
Best results were obtained with the YMC ODS-AQThe full-scan mass spectra of capecitabine, 59-
column. ODS-AQ is a reversed-phase material that isDFCR, 59-DFUR, and 5-CUDR are shown in Fig. 4. prepared with a monomeric bonding of octa-From these spectra, it is apparent that higher de- decylsilane (ODS) followed by addition of a hydro-
tection sensitivities could be achieved by monitoring philic endcapping reagent. The hydrophilic endcap1quasi-molecular ions [capecitabine1H] at m /z 360,
creates a surface that can be wetted with polar1 2[59-DFCR1H] at m /z 246, [59-DFUR2H] at m /z
eluents and does not undergo phase collapse even in245. Therefore, these ions were chosen for quantita- 100% water. In aqueous acidic conditions, the hydro-
tion in the subsequent studies. For internal standard philic endcap may protect the silane bond from(5-CUDR), the negative full-scan produced a much hydrolysis and results in a longer lifetime. Because
cleaner mass spectrum than the positive one with
there are more C chains available for interaction,18comparable detection sensitivity. Hence, [5-CUDR2 ODS-AQ material has stronger retention to polar2H] at m /z 261 was used for the subsequent
compounds than conventionally endcapped ODS
analyses. Single-ion-monitoring (SIM) mode was
materials in aqueous mobile phases.
used for quantitative analysis. The specificity for In LC–ESI-MS, the choices of mobile phasedetecting capecitabine, 59-DFCR, 59-DFUR, and 5-
composition, pH, and flow-rate are restrained by theCUDR is illustrated by the representative mass
conditions that are suitable for both LC separation
chromatograms from human plasma in Fig. 5. Co-
and ESI-MS detection. In general, ESI-MS requires
eluting endogenous compounds (i.e. the unknowns)
the use of volatile solvent additives to prevent
and other potential interfering metabolites (i.e. 5-
clogging of the sample orifice. The solvent additivesFUDR and 5-FUR) could be separated by the proper do not neutralize the analyte ions in gaseous phase
chromatographic conditions. by ion pairing, and can control the pH of the mobile
phase to promote the formation of analyte ions.
A gradient elution method that uses both 5 mM
Chromatographic conditions ammonium acetate (pH 6.8) and acetonitrile as
solvents has been optimized with the consideration
A useful analytical method should permit res- of on-line sample extraction, LC separation, and
olution and detection of the analytes of interest and ESI-MS detection. For example, although the use of
the internal standard from other interfering metabo- 1% acetic acid as mobile phase A in the gradient
lites and co-eluting endogenous compounds. In this elution method resulted in good LC separation, its
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Fig. 4. Full-scan mass spectra of capecitabine, 59-deoxy-5-fluorocytidine, 59-deoxy-5-fluorouridine and 5-chloro-29-deoxyuridine delivered directly to the MS detector. The
analyte concentration was 250 ng/ml, the flow injection carrier fluid was 5 mM ammonium acetate, pH 6.8, and the flow-rate was 0.1 ml /min.
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Fig. 5. Representative SIM chromatograms of plasma spiked to give a final concentration of 10.0 mg/ml each for capecitabine, 59-DFCR
and 59-DFUR, 20.0 mg/ml each for 5-FdUrd and 5-FUrd, and 2.50 mg/ml for 5-CdUrd. The injection volume was 20 ml. The experimental
conditions are described in Section 2.7. The unknown peaks at 11.99 min (m /z 246) and 13.32 min (m /z 261) have mass spectra that are
distinct from the compounds of interest.
use in the preparation and dilution of the calibrator these values were quite consistent throughout the
and samples did not result in reproducible peak areas concentration range studied (0.250–25.0 mg/ml).
for the parent compound, which might be caused by The intra- and inter-assay precision of the method
capecitabine degradation under the acidic conditions. was determined using plasma calibrators of
capecitabine, 5-DFCR and 5-DFUR at three con-
Analytical performance centration levels, and three replicates were assayed
for each data point (Table 4). The method had
The recovery of the compounds of interest from excellent intra- and inter-assay precision for
plasma was compared to the identical concentrations capecitabine, 5-DFCR and 5-DFUR, which ranged
prepared directly in mobile phase without further from 0.4% to 4.1% and 0.8% to 6.1%, respectively.
processing (Table 3). The average recoveries were Good linear relationships were found between the
99.0%, 99.0%, 73.8% and 81.4% for capecitabine, peak-area ratios of the analytes to 5-CUDR over the
5-DFCR, 5-DFUR and 5-CUDR, respectively, and concentration range of 0.0500–10.0 mg/ml for
Table 3
Recovery of capecitabine, 59-DFCR, 59-DFUR and 5-CUDR from human plasma
Compounds 0.25 mg/ml 2.5 mg/ml 25.0 mg/ml
% Recovery % C.V. % Recovery % C.V. % Recovery % C.V.
Capecitabine 99.0 0.8 100.0 2.8 98.0 6.3
59-DFCR 99.1 6.1 100.4 1.1 97.4 2.4
59-DFUR 74.8 1.4 73.4 2.6 73.1 3.1
I.S. 81.6 0.8 81.9 1.2 80.8 0.9




Intra- and inter-assay precision for plasma samples
Compounds 0.25 mg/ml 2.5 mg/ml 25.0 mg/ml
Peak area SD % C.V. Peak area SD % C.V. Peak area SD % C.V.
Intra-run
Capecitabine 469,301 3603 0.8 3,760,443 31,566 0.8 20,439,533 194,849 1.0
59-DFCR 11,147 457 4.1 127,202 1834 1.4 1,154,284 44,847 3.9
59-DFUR 14,857 414 2.8 174,039 710 0.4 1,670,678 10,057 0.6
5-CUDR 159,163 432 0.3 163,398 1340 0.8 166,771 1980 1.2
Between-run
Capecitabine 471,069 3640 0.8 3,729,965 102,646 2.8 20,470,941 273,124 1.3
59-DFCR 11,662 710 6.1 127,642 1400 1.1 1,176,086 70,802 6.0
59-DFUR 15,554 211 1.4 172,212 4540 2.6 1,628,049 38,040 2.3
5-CUDR 160,747 133 0.8 165,547 4986 1.2 162,034 2360 1.5
The data, shown as the mean6SD, represent samples prepared in triplicate injected either during the same run or on 3 different days. The
concentration of the internal standard, 5-CUDR, was constant at 2.5 mg/ml.
capecitabine, and 0.0500–25.0 mg/ml for 5-DFCR veloped can be used to accurately quantitate the
and 5-DFUR. The correlation coefficients for each of plasma concentrations of capecitabine, 5-DFCR, and
the calibration curves were above 0.99. 5-DFUR.
The limits of quantitations defined as 10 times the
signal-to-noise ratio were 0.0278 ng or 1.40 ng/ml
for plasma capecitabine, 0.352 ng or 17.6 ng/ml for Conclusion
plasma 5-DFCR, and 0.167 ng or 8.40 ng/ml for
plasma 5-DFUR with an injection volume of 20 ml Roche Laboratories has reported two different
(Fig. 6). These limits of quantitation were substan- methods for the analysis of capecitabine, 59-DFCR
tially lower than those of the current LC–UV and 59-DFUR in human plasma samples. In both
methods [9]. methods, 0.5 ml plasma is deproteinized with 1 ml
acetonitrile; after vortex-mixing and centrifugation,
Pharmacokinetic studies the supernatant is subjected to C solid-phase18
extraction, and the eluent is concentrated to dryness.
Blood samples collected prior to dosing indicated With the LC–UV method, two distinct chromatog-
that endogenous compounds did not interfere with raphy columns and separation conditions were re-
the analyses. MassLynx NT software was used to quired to detect either capecitabine or its two nu-
calculate the concentration of capecitabine, 5-DFCR, cleoside metabolites. With the LC–MS–MS method,
and 5-DFUR based on the peak area ratios of the residue obtained from SPE containing
capecitabine, 5-DFCR, and 5-DFUR with the internal capecitabine, 59-DFCR and 59DFUR was re-sus-
standard 5-CdUrd. A representative profile of these pended in 100 ml ammonium acetate, and 25 ml were
compounds in human plasma is shown in Fig. 7, and injected into an LC system equipped with a Supel-
a summary of the pharmacokinetic parameters fol- cosil ABS1 C column (150 mm32.0 mm) and a18
lowing the initial dose of capecitabine in four gradient mobile phase containing 10 mM ammonium
patients is shown in Table 5. In contrast to previous formate–acetonitrile. Further details were not pro-
reports, we found that the AUC of 59-DFCR was at vided, making it problematic for a non-affiliated
least as high or higher than that of 59-DFUR, which laboratory to reproduce the method.
is likely explained by our use of a cytidine deamin- We felt it was important to plan for the analysis of
ase inhibitor in the blood collection tubes. These any possible pharmacokinetic interactions between
results indicate that the LC–ESI-MS method de- capecitabine and oxaliplatin for our phase I trial. To
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Fig. 6. SIM chromatograms of blank plasma and plasma calibrators containing capecitabine, 59-DFCR and 59-DFUR. Analyte
concentrations, 50 ng/ml; injection volume, 20 ml; 1 ng injected. Experimental conditions were the same as Fig. 5.
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Fig. 7. Profiles of the plasma concentrations of capecitabine, 59-DFCR and 59-DFUR determined by the LC–ESI-MS method are shown for
2
subject 18 following capecitabine 1650 mg (750 mg/m ) alone (left panel) or immediately following a 2-h intravenous infusion of
2
oxaliplatin 130 mg/m (right panel).
enable this analysis, we developed a novel, validated ranges, sensitivity, high precision, and excellent
LC–MS assay that is capable of simultaneously analyte recoveries, it offers a viable alternative to the
measuring capecitabine, 5-DFCR and 5-DFUR in proprietary methods. Our method has successfully
human plasma with direct sample injection. Com- been used in the analysis of plasma samples from
pared to the off-line sample preparations previously patients participating in a phase I clinical trial of
described, our on-line sample clean-up offers an escalating doses of capecitabine ranging from 1300
advantage in terms of efficiency, precision, and cost. to 3300 mg given twice per day (total 2600–6600




T (h) 1 2 2max
(0.5–3) (0.5–3) (0.5–3)
C (mg/ml) 5.93 6.55 4.36max
(1.97–24.26) (2.94–8.27) (3.26–6.73)
AUC (mg/ml h) 7.79 13.69 9.19last
(3.38–14.58) (7.99–18.37) (7.37–11.91)
T (h) 0.34 1.02 0.671 / 2
(0.20–0.56) (0.61–1.44) (0.56–1.37)
2The data, presented as the median (range), are from four patients following their initial oral capecitabine dose of 1650 mg (750 mg/m ),
2 2
n51, 2150 mg (1050 mg/m ), n52, and 2450 mg (1200 mg/m ), n51.
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